17.31
+0.03(+0.17%)
Currency In USD
| Previous Close | 17.28 |
| Open | 17.36 |
| Day High | 17.5 |
| Day Low | 17.06 |
| 52-Week High | 21.48 |
| 52-Week Low | 4.47 |
| Volume | 149,420 |
| Average Volume | 467,355 |
| Market Cap | 464.21M |
| PE | -115.4 |
| EPS | -0.15 |
| Moving Average 50 Days | 15.33 |
| Moving Average 200 Days | 14.87 |
| Change | 0.03 |
If you invested $1000 in Eton Pharmaceuticals, Inc. (ETON) since IPO date, it would be worth $2,769.6 as of August 30, 2025 at a share price of $17.31. Whereas If you bought $1000 worth of Eton Pharmaceuticals, Inc. (ETON) shares 5 years ago, it would be worth $2,207.91 as of August 30, 2025 at a share price of $17.31.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Eton Pharmaceuticals to Participate at 2025 Wells Fargo Healthcare Conference
GlobeNewswire Inc.
Aug 20, 2025 10:50 AM GMT
DEER PARK, Ill., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that
Eton Pharmaceuticals to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025
GlobeNewswire Inc.
Jul 28, 2025 11:00 AM GMT
DEER PARK, Ill., July 28, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that
Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-600 (Desmopressin Oral Solution)
GlobeNewswire Inc.
Jul 08, 2025 10:50 AM GMT
- NDA assigned a Target Action Date of February 25, 2026 -- Product has patent protection through 2044 - DEER PARK, Ill., July 08, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceut